FRE.DE - Fresenius SE & Co. KGaA

XETRA - XETRA Delayed Price. Currency in EUR
42.94
+0.14 (+0.33%)
At close: 5:35PM CET
Stock chart is not supported by your current browser
Previous Close42.80
Open42.90
Bid0.00 x 120700
Ask0.00 x 6100
Day's Range42.83 - 43.65
52 Week Range38.28 - 71.36
Volume1,572,054
Avg. Volume2,339,804
Market Cap23.945B
Beta (3Y Monthly)0.31
PE Ratio (TTM)11.84
EPS (TTM)3.63
Earnings DateFeb 20, 2019
Forward Dividend & Yield0.75 (1.74%)
Ex-Dividend Date2018-05-22
1y Target EstN/A
  • Fresenius SE & Co. KGaA (FRA:FRE): A Fundamentally Attractive Investment
    Simply Wall St.2 days ago

    Fresenius SE & Co. KGaA (FRA:FRE): A Fundamentally Attractive Investment

    Attractive stocks have exceptional fundamentals. In the case of Fresenius SE & Co. KGaA (FRA:FRE), there's is a notable dividend-paying company with a a great history of performance, trading at Read More...

  • Reuters7 days ago

    Akorn gets FDA warning letter for Illinois plant, shares drop

    Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year. The warning letter, dated Friday, lists violations related to the agency's current good manufacturing practice regulations, which include poor aseptic behavior, as well as those related to environmental and personnel monitoring. The FDA said the company's response to its Form 483, which lists observations from the inspection in April and May, was inadequate.

  • Is Fresenius SE & Co. KGaA’s (FRA:FRE) 15% Better Than Average?
    Simply Wall St.29 days ago

    Is Fresenius SE & Co. KGaA’s (FRA:FRE) 15% Better Than Average?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...

  • Moody'slast month

    Akorn, Inc. -- Moody's downgrades Akorn's ratings to Caa1; outlook revised to negative

    Moody's Investors Service ("Moody's") downgraded the ratings of Akorn, Inc. ("Akorn") including the Corporate Family Rating to Caa1 from B3, the Probability of Default Rating to Caa1-PD from B3-PD and the senior secured term loan rating to Caa1 from B3. Moody's also downgraded the Speculative Grade Liquidity Rating to SGL-3 from SGL-2.

  • Reuterslast month

    Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

    Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE. The move comes after the Delaware Supreme Court on Friday upheld a decision by a lower court to allow Fresenius to walk away from its over $4 billion acquisition of Akorn that sent shares of the U.S generic drugmaker down more than 30 percent in regular trading. Akorn said that its Chief Executive Officer Raj Rai will retire but will remain in his post till a successor is named.

  • CNBClast month

    Stocks making the biggest moves premarket: Big Lots, Amazon, Tesla, Cronos, Lululemon & more

    Tobacco product Altria MO is buying a 45 percent stake in the cannabis producer for $1.8 billion. Big Lots BIG – The discount retailer l ost 16 cents per share for its latest quarter, wider than the one cent loss analysts were expecting. Revenue did beat forecasts, and a comparable store sales increase of 3.4 percent was above the consensus estimate of 2.9 percent.

  • The Wall Street Journallast month

    [$$] Fresenius Tumbles on Revised Outlook

    (FRE.XE) fell sharply Friday morning after the German healthcare provider adjusted its midterm guidance and warned it would miss its 2020 group targets late Thursday. Fresenius said it expects to see mid-single-digit organic sales growth for 2019 compared with earlier forecasts that had group sales increasing at a compounded annual growth rate, or CAGR, of 7.1% to 10.3% through 2020. Net income for 2019 would remain “broadly stable” compared with 2018, Fresenius said.

  • Here's Why Akorn Pharmaceuticals Is Sinking Today
    Motley Foollast month

    Here's Why Akorn Pharmaceuticals Is Sinking Today

    It looks as if the company's former suitor will get a chance to run from the altar.

  • Interested In Fresenius SE & Co KGaA (FRA:FRE)? Here’s What Its Recent Performance Looks Like
    Simply Wall St.2 months ago

    Interested In Fresenius SE & Co KGaA (FRA:FRE)? Here’s What Its Recent Performance Looks Like

    Today I will examine Fresenius SE & Co KGaA’s (FRA:FRE) latest earnings update (30 September 2018) and compare these figures against its performance over the past couple of years, in Read More...

  • Reuters2 months ago

    Germany's Bonitas and Median to join run of health services deals -sources

    Germany's fragmented healthcare services sector is poised to continue its recent consolidation with imminent sales of Bonitas Holding and Median Kliniken, sources close to the matter said. France's LVL Medical has put home care provider Bonitas up for sale with the help of investment bank Rothschild, three sources told Reuters, adding that Triton, Nordic Capital, Advent and GHO Capital have been shortlisted as potential buyers with an expected valuation of 250-300 million euros ($283 million to $340 million). Private equity investor Waterland, meanwhile, has shortlisted suitors in an auction for Median Kliniken, Germany's largest private-sector chain of post-acute care clinics, three other sources said.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FRE.DE earnings conference call or presentation 30-Oct-18 1:00pm GMT

    Q3 2018 Fresenius SE & Co KGaA Earnings Call

  • Here's Why Akorn, Inc. Fell 48.6% in October
    Motley Fool2 months ago

    Here's Why Akorn, Inc. Fell 48.6% in October

    A judge gave Fresenius the green light to walk away from the now-infamous merger.

  • Associated Press3 months ago

    Fresenius: 3Q Earnings Snapshot

    The Bad Homburg, Germany-based company said it had profit of 54 cents per share. Earnings, adjusted for non-recurring costs, came to 69 cents per share. The dialysis services provider posted revenue of ...

  • The Wall Street Journal3 months ago

    [$$] European Corporate Roundup

    European Corporate Roundup BP Swimming in Cash as Earnings Soar on High Oil Prices BP PLC said Tuesday its profit more than doubled in the third quarter, as strong crude prices put Big Oil on track to deliver record levels of cash this year.

  • Simply Wall St.3 months ago

    Does Fresenius SE & Co KGaA (FRA:FRE) Generate Enough Cash?

    Fresenius SE & Co KGaA (FRA:FRE) shareholders, and potential investors, need to understand how much cash the business makes from its core operational activities, as well as how much is Read More...

  • Reuters3 months ago

    Fresenius says working to fix performance at dialysis business, German hospitals

    Germany's Fresenius (FREG.DE) said it was putting measures in place to improve growth at its dialysis and German hospitals businesses after a weaker performance of these units prompted the group to narrow its guidance earlier this month. Chief Executive Stefan Sturm said Fresenius's dialysis business, Fresenius Medical Care, and its German hospital chain would "enhance their efforts to further improve and adapt to changing market conditions". Earlier this month, Fresenius said it now expected net income to grow at the low end of the original 6 to 9 percent range, when adjusted for currency swings.

  • Simply Wall St.3 months ago

    How Many Fresenius SE & Co KGaA (FRA:FRE) Shares Do Institutions Own?

    Every investor in Fresenius SE & Co KGaA (FRA:FRE) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, Read More...

  • Reuters3 months ago

    AbbVie settles Humira biosimilar dispute with Fresenius Kabi

    In the European Union, Fresenius Kabi can launch its biosimilar upon approval from the European Medicines Agency, while the license period in the United States will begin on Sept. 30, 2023, AbbVie said. Fresenius Kabi will pay royalties to AbbVie for licensing its patents for Humira, which is used to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis.

  • Reuters3 months ago

    AbbVie settles Humira biosimilar dispute with Fresenius Kabi

    U.S. drugmaker AbbVie Inc said on Thursday it has settled a patent dispute regarding its Humira biosimilar with Fresenius Kabi Oncology Ltd and will grant the Germany-based company non-exclusive marketing rights for the drug. In the European Union, Fresenius Kabi can launch its biosimilar upon approval from the European Medicines Agency, while the license period in the United States will begin on Sept. 30, 2023, AbbVie said.